换一批摘要Dear Editor,Lung adenocarcinoma(LUAD)is a major subtype of non-small cell lung cancer with global health implications.Targeted therapies,such as epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs),have demonstrated promise but encounter resistance challenges.Erlotinib(ER),a widely used EGFR TKI,often faces the emergence of resistance[1].Therefore,understanding therapeutic targets for ER resistance is crucial.AKR1C3 plays a pivotal role as a key enzyme in the biosynthesis of androgens,serving as a regulator of hormone activity and prostaglandin F synthase.
更多相关知识
关键词
AKR1C3Erlotinib resistanceEpidermal growth factor receptor(EGFR)mutationLung adenocarcinoma(LUAD)Therapeutic target
栏目名称
DOI
10.1186/s40779-025-00593-4
发布时间
2025-11-28（万方平台首次上网日期，不代表论文的发表时间）
- 浏览2
- 被引0
- 下载0
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
